Scemblix

(Asciminib)

Scemblix

Drug updated on 11/15/2023

Dosage FormFilm-coated tablet (oral; 20 mg, 40 mg)
Drug ClassKinase inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, previously treated with two or more tyrosine kinase inhibitors (TKIs).
  • For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase with the T315I mutation.

Product Monograph / Prescribing Information

Document TitleYearSource
Scemblix (asciminib) Prescribing Information.2023Novartis Pharmaceuticals Corporation, East Hanover, NJ

Systematic Reviews / Meta-Analyses